Atea Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US04683R1068

Introduction

This page provides a comprehensive analysis of the known insider trading history of Hack Andrew A. F.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Hack Andrew A. F. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:NUVL / Nuvalent, Inc. Director 1,447,267
US:DVAX / Dynavax Technologies Corporation Director 915,000
US:MRSN / Mersana Therapeutics, Inc. Director 14,467
US:ALNA / Allena Pharmaceuticals Inc Director 14,000
US:AVIR / Atea Pharmaceuticals, Inc. Director 0
US:BLSA / BCLS Acquisition Corp - Class A Chief Financial Officer, Director, 10% Owner 487,500
US:EDIT / Editas Medicine, Inc. Chief Financial Officer 9,618
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Hack Andrew A. F.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases AVIR / Atea Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AVIR / Atea Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2020-11-03 AVIR Hack Andrew A. F. 250,000 24.0000 250,000 24.0000 6,000,000 97 88.44 16,110,000 268.50

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AVIR / Atea Pharmaceuticals, Inc. Insider Trades
Insider Sales AVIR / Atea Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AVIR / Atea Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AVIR / Atea Pharmaceuticals, Inc. Insider Trades
Insider Purchases EDIT / Editas Medicine, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AVIR / Atea Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EDIT / Editas Medicine, Inc. Insider Trades
Insider Sales EDIT / Editas Medicine, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AVIR / Atea Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2018-03-20 EDIT Hack Andrew A. F. 22,000 37.9100 22,000 37.9100 834,020 276 18.1900 -433,840 -52.02
2017-02-15 EDIT Hack Andrew A. F. 3,000 19.2000 3,000 19.2000 57,600

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EDIT / Editas Medicine, Inc. Insider Trades
Insider Purchases MRSN / Mersana Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AVIR / Atea Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2022-06-02 MRSN Hack Andrew A. F. 14,760 3.1966 590 79.9150 47,182 342 8.0800 -42,414 -89.90
2022-05-31 MRSN Hack Andrew A. F. 80,759 3.2786 3,230 81.9650 264,776
2022-05-26 MRSN Hack Andrew A. F. 75,000 3.1859 3,000 79.6475 238,942
2022-05-25 MRSN Hack Andrew A. F. 90,155 3.1750 3,606 79.3750 286,242
2022-05-24 MRSN Hack Andrew A. F. 100,000 3.2899 4,000 82.2475 328,990
2022-05-23 MRSN Hack Andrew A. F. 15,599 3.3494 624 83.7350 52,247
2022-05-20 MRSN Hack Andrew A. F. 100,000 3.4557 4,000 86.3925 345,570
2022-05-19 MRSN Hack Andrew A. F. 100,000 3.4862 4,000 87.1550 348,620
2022-05-18 MRSN Hack Andrew A. F. 211,268 3.3477 8,451 83.6925 707,262
2022-05-17 MRSN Hack Andrew A. F. 3,440 3.1838 138 79.5950 10,952
2022-05-16 MRSN Hack Andrew A. F. 135,292 3.1003 5,412 77.5075 419,446
2022-04-13 MRSN Hack Andrew A. F. 617,284 4.0500 24,691 101.2500 2,500,000
2022-04-12 MRSN Hack Andrew A. F. 598,086 4.1798 23,923 104.4950 2,499,880
2022-02-07 MRSN Hack Andrew A. F. 1,136,363 4.4200 45,455 110.5000 5,022,724
2021-12-30 MRSN Hack Andrew A. F. 815,000 6.1500 32,600 153.7500 5,012,250
2021-12-29 MRSN Hack Andrew A. F. 875,000 5.7500 35,000 143.7500 5,031,250
2021-01-12 MRSN] Hack Andrew A. F. 75,000 18.1600 3,000 454.0000 1,362,000
2021-01-11 MRSN] Hack Andrew A. F. 75,000 18.5200 3,000 463.0000 1,389,000
2021-01-08 MRSN] Hack Andrew A. F. 100,000 18.3900 4,000 459.7500 1,839,000
2020-04-07 MRSN Hack Andrew A. F. 2,800,000 5.5900 112,000 139.7500 15,652,000
2020-04-07 MRSN Hack Andrew A. F. 645,667 7.7400 25,827 193.5000 4,997,463

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MRSN / Mersana Therapeutics, Inc. Insider Trades
Insider Sales MRSN / Mersana Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AVIR / Atea Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MRSN / Mersana Therapeutics, Inc. Insider Trades
Insider Purchases NUVL / Nuvalent, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AVIR / Atea Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2022-11-03 NUVL Hack Andrew A. F. 149,253 33.5000 149,253 33.5000 4,999,976 337 64.5200 4,629,829 92.60
2021-08-02 NUVL Hack Andrew A. F. 735,000 17.0000 735,000 17.0000 12,495,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NUVL / Nuvalent, Inc. Insider Trades
Insider Sales NUVL / Nuvalent, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AVIR / Atea Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2024-12-11 NUVL Hack Andrew A. F. 1,250,000 88.0000 1,250,000 88.0000 110,000,000 118 59.3200 -35,850,000 -32.59
2024-03-27 NUVL Hack Andrew A. F. 88,205 76.8807 88,205 76.8807 6,781,262
2024-03-27 NUVL Hack Andrew A. F. 791,795 72.3100 791,795 72.3100 57,254,696

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NUVL / Nuvalent, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Hack Andrew A. F. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-12-13 2024-12-11 4 NUVL Nuvalent, Inc.
Class A Common Stock
S - Sale -1,250,000 1,447,267 -46.34 88.00 -110,000,000 127,359,496
2024-06-14 2024-06-12 4 NUVL Nuvalent, Inc.
Class A Common Stock
A - Award 2,499 2,499
2024-03-29 2024-03-27 4 NUVL Nuvalent, Inc.
Class A Common Stock
S - Sale -791,795 2,697,267 -22.69 72.31 -57,254,696 195,039,377
2024-03-29 2024-03-27 4 NUVL Nuvalent, Inc.
Class A Common Stock
S - Sale -88,205 3,489,062 -2.47 76.88 -6,781,262 268,241,529
2023-08-10 2023-08-08 4 DVAX DYNAVAX TECHNOLOGIES CORP
Common Stock
S - Sale -1,500,000 915,000 -62.11 14.39 -21,585,000 13,166,850
2023-06-16 2023-06-14 4 DVAX DYNAVAX TECHNOLOGIES CORP
Common Stock
S - Sale -500,000 2,415,000 -17.15 12.68 -6,340,000 30,622,200
2023-06-12 2023-06-08 4 MRSN Mersana Therapeutics, Inc.
Common Stock
A - Award 14,467 14,467
2023-05-31 2023-05-26 4 DVAX DYNAVAX TECHNOLOGIES CORP
Common Stock
A - Award 5,357 10,714 100.00
2023-05-19 2023-05-18 4 DVAX DYNAVAX TECHNOLOGIES CORP
Common Stock
S - Sale -1,000,000 2,915,000 -25.54 10.55 -10,550,000 30,753,250
2022-12-08 2022-12-06 4 DVAX DYNAVAX TECHNOLOGIES CORP
Common Stock
S - Sale -1,500,000 3,915,000 -27.70 11.60 -17,400,000 45,414,000
2022-11-03 2022-11-03 4 NUVL Nuvalent, Inc.
Class A Common Stock
P - Purchase 149,253 3,577,267 4.35 33.50 4,999,976 119,838,444
2022-08-17 2022-08-15 4 DVAX DYNAVAX TECHNOLOGIES CORP
Common Stock
S - Sale -3,000,000 5,415,000 -35.65 14.68 -44,040,000 79,492,200
2022-06-02 2022-06-02 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 14,760 8,663,673 0.17 3.20 47,182 27,694,297
2022-06-02 2022-05-31 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 80,759 8,648,913 0.94 3.28 264,776 28,356,326
2022-05-27 2022-05-26 4 DVAX DYNAVAX TECHNOLOGIES CORP
Option (Right to Buy)
A - Award 22,500 22,500
2022-05-27 2022-05-26 4 DVAX DYNAVAX TECHNOLOGIES CORP
Restricted Stock Unit
A - Award 5,357 5,357
2022-05-26 2022-05-26 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 75,000 8,568,154 0.88 3.19 238,942 27,297,282
2022-05-26 2022-05-25 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 90,155 8,493,154 1.07 3.18 286,242 26,965,764
2022-05-26 2022-05-24 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 100,000 8,402,999 1.20 3.29 328,990 27,645,026
2022-05-23 2022-05-23 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 15,599 8,302,999 0.19 3.35 52,247 27,810,065
2022-05-23 2022-05-20 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 100,000 8,287,400 1.22 3.46 345,570 28,638,768
2022-05-23 2022-05-19 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 100,000 8,187,400 1.24 3.49 348,620 28,542,914
2022-05-18 2022-05-18 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 211,268 8,087,400 2.68 3.35 707,262 27,074,189
2022-05-18 2022-05-17 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 3,440 7,876,132 0.04 3.18 10,952 25,076,029
2022-05-18 2022-05-16 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 135,292 7,872,692 1.75 3.10 419,446 24,407,707
2022-04-14 2022-04-13 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 617,284 7,737,400 8.67 4.05 2,500,000 31,336,470
2022-04-13 2022-04-12 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 598,086 7,120,116 9.17 4.18 2,499,880 29,760,661
2022-02-08 2022-02-07 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 1,136,363 6,522,030 21.10 4.42 5,022,724 28,827,373
2022-01-05 2022-01-03 4 MRSN Mersana Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 10,995 10,995
2022-01-04 2021-12-30 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 815,000 5,385,667 17.83 6.15 5,012,250 33,121,852
2022-01-03 2021-12-29 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 875,000 4,570,667 23.68 5.75 5,031,250 26,281,335
2021-08-27 2021-08-27 4 DVAX DYNAVAX TECHNOLOGIES CORP
Series B Convertible Preferred Stock
C - Conversion -1,891 0 -100.00
2021-08-27 2021-08-27 4 DVAX DYNAVAX TECHNOLOGIES CORP
Common Stock
S - Sale -2,000,000 8,415,000 -19.20 16.22 -32,440,000 136,491,300
2021-08-27 2021-08-27 4 DVAX DYNAVAX TECHNOLOGIES CORP
Common Stock
C - Conversion 1,891,000 10,415,000 22.18
2021-08-11 2021-08-09 4 DVAX DYNAVAX TECHNOLOGIES CORP
Series B Convertible Preferred Stock
C - Conversion -2,249 1,891 -54.32
2021-08-11 2021-08-09 4 DVAX DYNAVAX TECHNOLOGIES CORP
Common Stock
S - Sale -2,250,000 8,524,000 -20.88 10.80 -24,300,000 92,059,200
2021-08-11 2021-08-09 4 DVAX DYNAVAX TECHNOLOGIES CORP
Common Stock
C - Conversion 2,249,000 10,774,000 26.38
2021-08-04 2021-08-02 4 NUVL Nuvalent, Inc.
Series B Preferred Stock
C - Conversion -14,494,154 0 -100.00
2021-08-04 2021-08-02 4 NUVL Nuvalent, Inc.
Class A Common Stock
P - Purchase 735,000 3,428,014 27.29 17.00 12,495,000 58,276,238
2021-08-04 2021-08-02 4 NUVL Nuvalent, Inc.
Class A Common Stock
C - Conversion 2,693,014 2,693,014
2021-07-30 2021-07-28 4 NUVL Nuvalent, Inc.
Stock Option (Right to Buy)
A - Award 43,000 43,000
2021-06-15 2021-06-11 4 MRSN] Mersana Therapeutics, Inc.
Stock Option (right to buy)
A - Award 25,050 25,050
2021-06-11 2021-06-10 4 DVAX DYNAVAX TECHNOLOGIES CORP
Warrants (Right to Buy)
S - Sale -2,916,250 0 -100.00
2021-06-02 2021-05-28 4 DVAX DYNAVAX TECHNOLOGIES CORP
Stock Option (Right to Buy)
A - Award 25,000 25,000
2021-01-20 2021-01-15 4 MRSN] Mersana Therapeutics, Inc.
Stock Option (right to buy)
A - Award 2,971 2,971
2021-01-12 2021-01-12 4 MRSN] Mersana Therapeutics, Inc.
Common Stock
P - Purchase 75,000 3,695,667 2.07 18.16 1,362,000 67,113,313
2021-01-12 2021-01-11 4 MRSN] Mersana Therapeutics, Inc.
Common Stock
P - Purchase 75,000 3,620,667 2.12 18.52 1,389,000 67,054,753
2021-01-12 2021-01-08 4 MRSN] Mersana Therapeutics, Inc.
Common Stock
P - Purchase 100,000 3,545,667 2.90 18.39 1,839,000 65,204,816
2020-11-18 2020-11-17 4 ALNA Allena Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 14,000 14,000
2020-11-03 2020-11-03 4 AVIR Atea Pharmaceuticals, Inc.
Series D-1 Convertible Preferred Stock
C - Conversion -1,982,469 0 -100.00
2020-11-03 2020-11-03 4 AVIR Atea Pharmaceuticals, Inc.
Series D Convertible Preferred Stock
C - Conversion -3,383,190 0 -100.00
2020-11-03 2020-11-03 4 AVIR Atea Pharmaceuticals, Inc.
Common Stock
P - Purchase 250,000 5,615,659 4.66 24.00 6,000,000 134,775,816
2020-11-03 2020-11-03 4 AVIR Atea Pharmaceuticals, Inc.
Common Stock
C - Conversion 5,365,659 5,365,659
2020-10-30 2020-10-29 4 AVIR Atea Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 80,000 80,000
2020-10-26 2020-10-26 4 BLSA BCLS Acquisition Corp.
Class A ordinary shares
A - Award 487,500 487,500 10.00 4,875,000 4,875,000
2020-05-29 2020-05-28 4 DVAX DYNAVAX TECHNOLOGIES CORP
Option (Right to Buy)
A - Award 18,750 18,750
2020-05-28 2020-05-27 4 DVAX DYNAVAX TECHNOLOGIES CORP
Common Stock
P - Purchase 1,000,000 8,525,000 13.29 5.00 5,000,000 42,625,000
2020-04-09 2020-04-07 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 645,667 3,445,667 23.06 7.74 4,997,463 26,669,463
2020-04-09 2020-04-07 4 MRSN Mersana Therapeutics, Inc.
Common Stock
P - Purchase 2,800,000 2,800,000 5.59 15,652,000 15,652,000
2020-03-12 2020-03-11 4 DVAX DYNAVAX TECHNOLOGIES CORP
Right to Exchange
A - Award 1 1
2019-08-22 3 DVAX DYNAVAX TECHNOLOGIES CORP
Common Stock
15,050,000
2019-08-22 3 DVAX DYNAVAX TECHNOLOGIES CORP
Common Stock
15,050,000
2019-08-22 3 DVAX DYNAVAX TECHNOLOGIES CORP
Common Stock
15,050,000
2019-08-14 2019-08-12 4 DVAX DYNAVAX TECHNOLOGIES CORP
Option (Right to Buy)
A - Award 15,000 15,000
2019-06-11 2019-06-07 4 MRSN Mersana Therapeutics, Inc.
Stock Option (right to buy)
A - Award 25,000 25,000
2019-06-07 2019-06-05 4 ALNA Allena Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 14,000 14,000
2019-02-06 2019-02-04 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -6,895 9,618 -41.75
2019-02-06 2019-02-04 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -6,895 0 -100.00 21.39 -147,484
2019-02-06 2019-02-04 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 6,895 6,895 6.48 44,680 44,680
2019-01-08 2019-01-04 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -7,000 16,513 -29.77
2019-01-08 2019-01-04 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -7,000 0 -100.00 22.48 -157,360
2019-01-08 2019-01-04 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 7,000 7,000 6.48 45,360 45,360
2019-01-08 2018-11-23 4/A EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -5,284 119,143 -4.25
2019-01-08 2018-11-23 4/A EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 5,284 5,284 3.23 17,067 17,067
2019-01-08 2018-10-26 4/A EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -6,000 124,427 -4.60
2019-01-08 2018-10-26 4/A EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 6,000 6,000 3.23 19,380 19,380
2018-11-27 2018-11-23 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -5,284 12,229 -30.17
2018-11-27 2018-11-23 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -100 0 -100.00 28.61 -2,861
2018-11-27 2018-11-23 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -5,184 100 -98.11 28.14 -145,878 2,814
2018-11-27 2018-11-23 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 5,284 5,284 6.48 34,240 34,240
2018-10-30 2018-10-26 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -6,000 17,513 -25.52
2018-10-30 2018-10-26 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -6,000 0 -100.00 25.70 -154,200
2018-10-30 2018-10-26 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 6,000 6,000 6.48 38,880 38,880
2018-10-02 2018-09-28 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -8,000 23,513 -25.39
2018-10-02 2018-09-28 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -8,000 0 -100.00 32.08 -256,640
2018-10-02 2018-09-28 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 8,000 8,000 6.48 51,840 51,840
2018-09-21 2018-09-20 4 MRSN Mersana Therapeutics, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2018-09-05 2018-08-31 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -10,000 31,513 -24.09
2018-09-05 2018-08-31 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -10,000 0 -100.00 32.23 -322,300
2018-09-05 2018-08-31 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 10,000 10,000 6.48 64,800 64,800
2018-06-12 2018-06-08 4 ALNA Allena Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 20,364 20,364
2018-06-05 2018-06-04 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -3,000 67,500 -4.26
2018-06-05 2018-06-04 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -3,000 0 -100.00 37.10 -111,300
2018-06-05 2018-06-04 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 3,000 3,000 24.60 73,800 73,800
2018-06-05 2018-06-01 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -7,000 41,513 -14.43
2018-06-05 2018-06-01 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -2,000 0 -100.00 39.86 -79,720
2018-06-05 2018-06-01 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 2,000 2,000 6.48 12,960 12,960
2018-06-05 2018-06-01 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -5,000 0 -100.00 39.05 -195,250
2018-06-05 2018-06-01 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 5,000 5,000 6.48 32,400 32,400
2018-03-20 2018-03-20 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise -22,000 70,500 -23.78
2018-03-20 2018-03-20 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -6,000 48,513 -11.01
2018-03-20 2018-03-20 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale -22,000 0 -100.00 37.91 -834,020
2018-03-20 2018-03-20 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise 22,000 22,000 24.60 541,200 541,200
2018-03-20 2018-03-20 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -1,000 0 -100.00 38.39 -38,390
2018-03-20 2018-03-20 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 1,000 1,000 6.48 6,480 6,480
2018-03-20 2018-03-20 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -5,000 0 -100.00 37.51 -187,550
2018-03-20 2018-03-20 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 5,000 5,000 6.48 32,400 32,400
2018-03-20 2018-03-19 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -6,000 54,513 -9.92
2018-03-20 2018-03-19 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -6,000 0 -100.00 37.65 -225,900
2018-03-20 2018-03-19 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 6,000 6,000 6.48 38,880 38,880
2018-03-20 2018-03-16 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -6,000 60,513 -9.02
2018-03-20 2018-03-16 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -6,000 0 -100.00 39.43 -236,580
2018-03-20 2018-03-16 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 6,000 6,000 6.48 38,880 38,880
2018-02-16 2018-02-16 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -6,000 63,662 -8.61
2018-02-16 2018-02-16 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -6,000 0 -100.00 35.32 -211,920
2018-02-16 2018-02-16 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 6,000 6,000 6.48 38,880 38,880
2018-02-16 2018-02-15 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -6,000 69,662 -7.93
2018-02-16 2018-02-15 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -6,000 0 -100.00 34.61 -207,660
2018-02-16 2018-02-15 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 6,000 6,000 6.48 38,880 38,880
2018-02-16 2018-02-14 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -6,000 75,662 -7.35
2018-02-16 2018-02-14 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -6,000 0 -100.00 32.71 -196,260
2018-02-16 2018-02-14 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 6,000 6,000 6.48 38,880 38,880
2018-02-09 2018-02-07 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
A - Award 95,000 95,000
2017-12-19 2017-12-19 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -4,649 130,427 -3.44
2017-12-19 2017-12-19 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -4,649 0 -100.00 25.06 -116,510
2017-12-19 2017-12-19 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 4,649 4,649 3.23 15,016 15,016
2017-12-19 2017-12-18 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -5,000 135,076 -3.57
2017-12-19 2017-12-18 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -5,000 0 -100.00 24.68 -123,409
2017-12-19 2017-12-18 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 5,000 5,000 3.23 16,150 16,150
2017-12-19 2017-12-15 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -5,000 140,076 -3.45
2017-12-19 2017-12-15 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -5,000 0 -100.00 24.31 -121,546
2017-12-19 2017-12-15 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 5,000 5,000 3.23 16,150 16,150
2017-11-21 2017-11-20 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -5,000 145,076 -3.33
2017-11-21 2017-11-20 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -5,000 0 -100.00 25.35 -126,732
2017-11-21 2017-11-20 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 5,000 5,000 3.23 16,150 16,150
2017-11-21 2017-11-17 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -5,000 150,076 -3.22
2017-11-21 2017-11-17 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -5,000 0 -100.00 24.81 -124,073
2017-11-21 2017-11-17 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 5,000 5,000 3.23 16,150 16,150
2017-03-03 2017-03-01 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
A - Award 92,500 92,500
2017-02-16 2017-02-15 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -3,000 155,076 -1.90
2017-02-16 2017-02-15 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale -3,000 0 -100.00 19.20 -57,600
2017-02-16 2017-02-15 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 3,000 3,000 3.23 9,690 9,690
2017-01-13 2017-01-11 4 EDIT Editas Medicine, Inc.
Stock Option (right to buy)
M - Exercise X -15,000 158,076 -8.67
2017-01-13 2017-01-11 4 EDIT Editas Medicine, Inc.
Common Stock
S - Sale X -15,000 0 -100.00 19.20 -288,000
2017-01-13 2017-01-11 4 EDIT Editas Medicine, Inc.
Common Stock
M - Exercise X 15,000 15,000 3.23 48,450 48,450
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)